Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of …
T Yoroidaka, T Yamashita, R Murata… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: Carfilzomib, lenalidomide, and dexamethasone (KRD) therapy is widely
used for patients with relapse/refractory multiple myeloma (RRMM). However, the response …
used for patients with relapse/refractory multiple myeloma (RRMM). However, the response …
Minimal residual disease assessment using EuroFlow in patients with relapsed/refractory multiple myeloma who received carfilzomib+ lenalidomide+ dexamethasone …
H Takamatsu, T Yoroidaka… - Clinical …, 2019 - clinical-lymphoma-myeloma …
Background Deep response has a great impact on prognosis in multiple myeloma (MM). We
treated patients with MM with carfilzomib+ lenalidomide+ dexamethasone (KRD) therapy …
treated patients with MM with carfilzomib+ lenalidomide+ dexamethasone (KRD) therapy …
[HTML][HTML] The utility of EuroFlow MRD assessment in real-world multiple myeloma practice
R Turner, A Kalff, K Bergin, M Gorniak… - Frontiers in …, 2022 - frontiersin.org
Measurable residual disease (MRD) is being recognised as an optimal method for
assessing depth of response, identifying higher risk of relapse, and guiding response-based …
assessing depth of response, identifying higher risk of relapse, and guiding response-based …
Measurable residual disease by next-generation flow cytometry in multiple myeloma
B Paiva, R Martinez-Martinez, R Maldonado, A Sureda… - 2020 - zaguan.unizar.es
PURPOSE: Assessing measurable residual disease (MRD) has become standard with many
tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain …
tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain …
[HTML][HTML] Minimal residual disease status predicts progression-free survival in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib …
J Jasielec, D Dytfeld, KA Griffith, K McDonnell… - Blood, 2014 - Elsevier
Background: NDMM patients (pts) treated with KRd in a phase 1/2 trial (NCT01029054)
demonstrated high rates of complete response (CR, 64%) and stringent complete response …
demonstrated high rates of complete response (CR, 64%) and stringent complete response …
[HTML][HTML] MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in …
N Korde, S Mailankody, EL Smith, N Lendvai… - Blood, 2017 - Elsevier
Introduction Newly diagnosed multiple myeloma (NDMM) patients achieving and
maintaining minimal residual disease (MRD) negativity demonstrate clinical benefit with …
maintaining minimal residual disease (MRD) negativity demonstrate clinical benefit with …
[HTML][HTML] Minimal residual disease evaluation by multiparameter flow cytometry and next generation sequencing in the forte trial for newly diagnosed multiple myeloma …
S Oliva, E Genuardi, A Belotti, PMM Frascione, M Galli… - Blood, 2019 - Elsevier
Background: The role of Minimal residual disease (MRD) as surrogate for survival in Multiple
Myeloma (MM) patients is well established. Therefore, new response criteria recommend …
Myeloma (MM) patients is well established. Therefore, new response criteria recommend …
[HTML][HTML] Evaluation of minimal residual disease (MRD) negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study
O Landgren, K Weisel, LR Dachs, P Moreau, M Turgut… - Blood, 2020 - Elsevier
Introduction: CANDOR is a multicenter, phase 3, randomized study of adult patients with
relapsed or refractory multiple myeloma (RRMM) previously treated with 1-3 prior lines of …
relapsed or refractory multiple myeloma (RRMM) previously treated with 1-3 prior lines of …
[HTML][HTML] Measurable residual disease assessment in multiple myeloma: how deep is enough?
J Caetano, F Barahona, P Lúcio, C João - Hemato, 2022 - mdpi.com
The introduction of new and more effective therapeutic options for Multiple Myeloma (MM)
has significantly deepened and prolonged patients' remission. As currently used treatment …
has significantly deepened and prolonged patients' remission. As currently used treatment …
[HTML][HTML] Impact of next-generation flow (NGF) minimal residual disease (MRD) monitoring in multiple myeloma (MM): results from the Pethema/GEM2012 trial
B Paiva, N Puig, MT Cedena, L Cordon, MB Vidriales… - Blood, 2017 - Elsevier
Background: MRD is an established biomarker to evaluate treatment efficacy, define patients
at risk based on persistent MRD, and eventually, act as surrogate for prolonged survival …
at risk based on persistent MRD, and eventually, act as surrogate for prolonged survival …
Related searches
- carfilzomib lenalidomide disease assessment
- disease evaluation myeloma patients
- multiparameter flow myeloma patients
- generation sequencing myeloma patients
- disease evaluation multiparameter flow
- ndmm patients disease status
- disease evaluation generation sequencing
- multiparameter flow generation sequencing
- combination of carfilzomib disease assessment